Page 12 - RxExam's Naplex Theory Book Part 2

www.pharmacyexam.com Krisman

Dose Special Notes

Filgrastim 3. PBPC: 3). A CBC and platelet count should be obtained before instituting
(Injection) 10 mcg/kg/day SC‚ Filgrastim (Neupogen) therapy‚ and monitored twice weekly during
either as a bolus therapy.
or a continuous
infusion. 4). For patients receiving bone marrow transplant (BMT)‚ the first dose
of Filgrastim (Neupogen) should be administered at least 24 hours
4. Congenital after cytotoxic chemotherapy and at least 24 hours after bone marrow
neutropenia: infusion.
6 mcg/kg BID SC
every day. 5). Nausea, vomiting, hypertension, rash, cutaneous vasculitis, acute
respiratory distress syndrome, splenic rupture, alveolar hemorrhage
5. Idiopathic or and hemoptysis, sickle cell crisis and sweet's syndrome (acute febrile
Cyclic Neutropenia neutrophilic dermatosis) are reported with Filgrastim (Neupogen)
5 mcg/kg as a therapy.
single injection SC
every day.

Pegfilgrastim Febrile neutropenia: 1). Pegfilgrastim (Neulasta) is a covalent conjugate of recombinant
(Injection) methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene
6 mg via SC given glycol.
once per
chemotherapy 2). Pegfilgrastim (Neulasta) is indicated to decrease the incidence of
cycle. infection, as manifested by febrile neutropenia, in patients with non-
myeloid malignancies receiving myelosuppressive anti-cancer drugs
associated with a clinically significant incidence of febrile neutropenia.

3). The 6 mg fixed-dose formulation should not be used in infants,
children, and smaller adolescents weighing less than 45 kg.

4). Pegfilgrastim (Neulasta) should NOT be administered in the period
between 14 days before and 24 hours after administration of cytotoxic
chemotherapy.

5). Nausea, vomiting, hypertension, rash, cutaneous vasculitis, acute
respiratory distress syndrome, splenic rupture, alveolar hemorrhage
and hemoptysis, sickle cell crisis and sweet's syndrome (acute febrile
neutrophilic dermatosis) are reported with Filgrastim (Neupogen)
therapy.

Sargramostim 250 mcg/m²/day 1). Sargramostim (Leukine) is a recombinant human granulocyte
(Injection) administered IV or macrophage colony stimulating factor (Rhu GM-CSF) produced by
SC depend on the recombinant DNA technology in a yeast (S. cerevisiae) expression
conditon treated. system. GM-CSF is a hematopoietic growth factor which stimulates
proliferation and differentiation of hematopoietic progenitor cells.

11